These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 15512875)

  • 1. Improving efficiency of ALS clinical trials using lead-in designs.
    Moore DH; Miller RG
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():57-60. PubMed ID: 15512875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.
    Levy G; Kaufmann P; Buchsbaum R; Montes J; Barsdorf A; Arbing R; Battista V; Zhou X; Mitsumoto H; Levin B; Thompson JL
    Neurology; 2006 Mar; 66(5):660-3. PubMed ID: 16534103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing clinical trials in amyotrophic lateral sclerosis.
    Shefner JM
    Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):495-508, ix. PubMed ID: 18625412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?
    de Carvalho M; Swash M
    Arch Neurol; 2006 Apr; 63(4):557-60. PubMed ID: 16606769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
    Gordon PH
    Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential designs for clinical trials in amyotrophic lateral sclerosis.
    Groeneveld GJ; van der Tweel I; Wokke JH; van den Berg LH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Dec; 5(4):202-7. PubMed ID: 15799547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ALS issues in clinical trials. Statistical issues.
    Levin B
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():43-5. PubMed ID: 15512870
    [No Abstract]   [Full Text] [Related]  

  • 8. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selecting promising ALS therapies in clinical trials.
    Cheung YK; Gordon PH; Levin B
    Neurology; 2006 Nov; 67(10):1748-51. PubMed ID: 17130405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiplicity and flexibility in clinical trials.
    Brannath W; Koenig F; Bauer P
    Pharm Stat; 2007; 6(3):205-16. PubMed ID: 17674349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements.
    de Carvalho M; Costa J; Swash M
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2005 Dec; 6(4):202-12. PubMed ID: 16319023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scrutinizing enrollment in ALS clinical trials: room for improvement?
    Bedlack RS; Pastula DM; Welsh E; Pulley D; Cudkowicz ME
    Amyotroph Lateral Scler; 2008 Oct; 9(5):257-65. PubMed ID: 18608092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome measures for early phase clinical trials.
    Gordon PH; Cheng B; Montes J; Doorish C; Albert SM; Mitsumoto H
    Amyotroph Lateral Scler; 2007 Oct; 8(5):270-3. PubMed ID: 17852017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we eliminate placebo in ALS clinical Trials?
    Simmons Z
    Muscle Nerve; 2009 Jun; 39(6):861-5. PubMed ID: 19382170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.
    Malta E
    Adv Neurol; 1995; 68():263-9; discussion 271-5. PubMed ID: 8787239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of database controls in pilot or futility studies in ALS.
    Czaplinski A; Haverkamp LJ; Yen AA; Simpson EP; Lai EC; Appel SH
    Neurology; 2006 Nov; 67(10):1827-32. PubMed ID: 17130417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of phase II ALS clinical trials.
    Schoenfeld DA; Cudkowicz M
    Amyotroph Lateral Scler; 2008; 9(1):16-23. PubMed ID: 18273715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials.
    Chen YF; Yang Y; Hung HM; Wang SJ
    Contemp Clin Trials; 2011 Jul; 32(4):592-604. PubMed ID: 21540126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal two-stage designs for clinical trials based on safety and efficacy.
    Thall PF; Cheng SC
    Stat Med; 2001 Apr; 20(7):1023-32. PubMed ID: 11276033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The need for more efficient trial designs.
    Golub HL
    Stat Med; 2006 Oct; 25(19):3231-5; discussion 3313-4, 3326-47. PubMed ID: 16819752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.